Objective To observe the clinical curative effect of Madopar and pramipexole in patients with Parkinson 's disease and impact on quality of life and the level of blood uric acid .Methods From January 2013 to June 2015,100 cases of Parkinson's disease were enrolled, in according to a random draw method , they were divided into observation group and control group, each of 50 cases, control group patients were treated with Madopar treatment , observation group also combined use of pramipexole, 2 groups of patients were treated for 3 months, then observed changes in the level of blood uric acid and clinical curative effect; assessment of the quality of life scale 2(QOL-2)score of two groups of patients before and after treatment , and Unified Parkinson's disease rating table (UPDRS) were assessed, and recorded adverse reactions .Results After the treat-ment, the total effective rate in observation group was significantly higher than that of the control (90.0% vs.52.0%,χ2 =55.117, P <0.05); in observation group, the level of blood uric acid higher than that of the control group [ (269.35 ± 80.45)μmol /L vs.(238.64 ±69.65)μmol/L, t =2.041, P <0.05), QOL-2 score and UPDRS scores were better than controls, differences were statistically significant ( P <0.05), 2 groups of patients in the course of treatment , the adverse re-actions occurred rate difference was not statistically significant (8.0% vs.14.0%,χ2 =0.919, P >0.05).Conclusion Madopar and pramipexole treatment for Parkinson 's disease can stabilize the patient's serum uric acid level, and effectively im-prove the quality of life of patients , improve clinical curative effect with high safety .%目的：观察美多巴联合普拉克索治疗帕金森病患者的临床疗效及对生活质量、血尿酸水平的影响。方法选择2013年1月—2015年6月重庆市第五人民医院神经内科治疗的帕金森病患者100例，按照随机抽签的方法分为观察组和对照组各50例，对照组患者使用美多巴进行治疗，观察组则在对照组基础上联合使用普拉克索治疗，2组患者均治疗3个月后，观察临床疗效与血尿酸水平的变化；对2组患者治疗前后的生活质量评定量表－2（QOL－2）评分与帕金森病统一评分量表（UPDRS）评分进行评定，并记录不良反应。结果治疗后观察组总有效率显著高于对照（90．0％ vs．52．0％，χ2＝55．117， P ＜0．05）；观察组血尿酸水平高于对照组[（269．35±80．45）μmol ／L vs．（238．64±69．65）μmol／L， t ＝2．041， P ＜0．05]，QOL－2评分与 UPDRS 评分均优于对照组，差异均有统计学意义（ P ＜0．05），2组患者在治疗过程中不良反应发生率比较差异无统计学意义（8．0％ vs．14．0％，χ2＝0．919， P ＞0．05）。结论美多巴联合普拉克索治疗帕金森病患者，能够稳定患者的血尿酸水平，并有效改善患者的生活质量以及运动功能，提高临床疗效，且安全性较高。
展开▼
